Early Phase Clinical Trials
Multi-disciplinary early phase approach accelerating proof of concept
Service · OtherCompany source
Company profile
About Parexel
Parexel is a leading global contract research organization (CRO) that provides comprehensive biopharmaceutical services spanning the entire drug development lifecycle. The company delivers end-to-end solutions from portfolio optimization and early phase clinical trials through Phase I-IV studies, regulatory submissions, market access planning, and post-approval lifecycle management. Parexel combines operational expertise with its proprietary ParexelAI technology suite to accelerate clinical development with greater speed, quality, and efficiency. The company specializes in multiple therapeutic areas including oncology, neuroscience, immunology, infectious diseases, hematology, ophthalmology, and rare diseases. Parexel's services encompass clinical trial management, regulatory strategy and submissions, real-world evidence generation, pharmacovigilance, medical communications, and market access consulting. With a team that includes more than 80 former regulatory agency professionals and access to nearly 2,500 clinical trial sites globally, Parexel serves pharmaceutical companies, biotech firms, and medical device manufacturers. The company offers flexible delivery models including functional service provider (FSP) arrangements and customized site solutions. Parexel's integrated approach combines clinical, regulatory, and market access expertise to optimize development strategies, accelerate patient enrollment, ensure regulatory compliance, and maximize the commercial potential of new therapies throughout their lifecycle.
Company description Parexel official website
Primary marketClinical Trials & Research
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Parexel?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Cell and gene therapies
- General medicine (gastroenterology, respiratory, endocrine/metabolic, cardiovascular, women's health)
- Hematology (lymphoma, AML, MDS, multiple myeloma)
- Immunology (dermatology, allergy)
- Infectious diseases and vaccines
- Neuroscience (neurology, psychiatry)
- Oncology (bladder, breast, colorectal, gynecologic, head and neck, liver, lung, pancreatic, prostate cancer)
- Ophthalmology
- Pediatrics
- Rare diseases
Who it serves
- Biotech firms
- Medical device manufacturers
- Pharmaceutical companies
Deployment & integration
Cloud Saas · Other deployment with recorded integration context.
Geographic context
MarketsGermany (Berlin trial site) · Global · UK (London trial site) · USA (Baltimore, Los Angeles trial sites)
Company sourceOfficial website
Company milestones
Platform expansion
ParexelAI platform launch and integration with Paradigm for AI-enabled clinical development
Partnerships
Recorded partners
- 2,500+ clinical trial sites globally
- Paradigm (mentioned in ParexelAI context)
- Site Alliance Network
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
FSP Delivery Models
Functional Service Provider models for clinical trials
Service · OtherCompany source
Global Regulatory Submissions and Outsourcing
Tailored regulatory and market access strategies for global reach
Service · OtherCompany source
ParexelAI
AI-enabled clinical development suite accelerating patient outcomes
Platform · Cloud SaaSCompany source
Phase IIB-IV Clinical Trials
Integrated clinical development with patient-informed protocols
Service · OtherCompany source
Portfolio Management and Asset Valuation
Optimize portfolios with integrated clinical, regulatory, and market access strategies
Service · OtherCompany source
Real-World Evidence
Post-approval studies and lifecycle management services
Service · OtherCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Infection Incidence and Survival in Patients With Multiple Myeloma and Chronic Lymphocytic Leukaemia: A Growing Concern in the Era of Modern Therapies.EJHaem · Aug 1, 2026
Patient outcomes in KCNQ2 developmental and epileptic encephalopathy.Developmental medicine and child neurology · Aug 1, 2026
Sleep Disturbance in Opioid Use Disorder: Systematic Review of Insomnia Prevalence and Sedative-Hypnotic Utilization.Substance use & misuse · Jul 19, 2026
Outcomes of nucleos(t)ide analogue discontinuation following finite xalnesiran-based therapies in chronic hepatitis B.JHEP reports : innovation in hepatology · Jul 15, 2026
Updated systematic literature review and network meta-analysis of cladribine tablets versus currently approved disease-modifying treatments for active relapsing-remitting multiple sclerosis.Multiple sclerosis and related disorders · Jul 1, 2026
Population Pharmacokinetics of Intranasal Amiloride in Healthy Volunteers.European journal of drug metabolism and pharmacokinetics · Jul 1, 2026
Clinical validation
Clinical-trial records
Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of SaruparibNCT06899061 · Sponsor · ACTIVE NOT RECRUITING
Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia PatientsNCT04008706 · Sponsor · COMPLETED
A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care TherapyNCT07161414 · Sponsor · RECRUITING
Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate CancerNCT07181161 · Sponsor · RECRUITING
A Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy ParticipantsNCT07534592 · Sponsor · ACTIVE NOT RECRUITING
A Study to Investigate the Safety and Pharmacokinetics of Single- and Multiple-ascending Doses of AZD4916 in Healthy VolunteersNCT06951880 · Sponsor · RECRUITING
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Accelerated patient outcomes
Through AI-enabled clinical development suite
Greater speed, quality, and efficiency
ParexelAI delivery capabilities
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from Parexel
Recent articles published on Parexel's official website.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Clinical Trials & Research
Companies using AI to optimize clinical trial design, accelerate patient recruitment, match patients to trials, predict trial outcomes, or improve clinical research efficiency. Includes patient enrollment and screening platforms, AI-powered trial matching, and tools that reduce the time and cost of bringing new treatments to market.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.